Single cell technologies for personalized medicine

The single cell technology is the basis for the second still active flagship application: "Life Time: Revolutionizing Healthcare by Tracking and Understanding Human Cells during Disease". This application is led by Prof. Rajewsky, who is also the coordinator of the focus area 'Single Cell Technologies for Personalized Medicine'.

In order to make the highly innovative single cell technologies clinically usable for effective translation as quickly as possible, BIH is establishing a jointly supported, close interdisciplinary cooperation, in which BIH and Charité will contribute clinic-related expertise (bioinformatics, imaging, machine learning, oncology, neurology, dermatology, biobanks, diagnostics and biomarkers) and the MDC/BIMSB technological and scientific expertise in the field of single cell biology and gene regulation.

The implementation is based on two pillars:

The establishment of three bridge junior research groups from BIH, MDC/BIMSB and Charité, which bring single cell expertise into clinical application. These junior research groups are located in the BIMSB building, where they have access to the latest single cell technologies and are in close contact with leading international scientists*. At the same time, each of these groups is integrated into a clinic at the Charité where they identify clinically relevant topics, use and develop single cell approaches to address specific clinical issues and establish the technologies for clinical use. This bridge concept optimally combines the internationally leading position of the BIMSB in the development of single cell technologies with the clinical-translational potential of BIH/Charité.

The development of a "Clinical Single Cell Sequencing" pipeline, which includes a central bioportal (patient sample collection, characterization and processing) as well as an integrated workflow with relevant genomics and bioinformatics services for the participating clinics.